Company Overview and News

 
Insurance industry shift from coal could mean higher power prices

2018-05-20 theage.com.au
A quiet revolution is happening in insurance, as many of the industry's big players pull their backing and investment from the coal power sector, potentially raising the price of electricity.

 
Insurance industry shift from coal could mean higher power prices

2018-05-20 smh.com.au
A quiet revolution is happening in insurance, as many of the industry's big players pull their backing and investment from the coal power sector, potentially raising the price of electricity.

 
Sumitomo Mitsui Financial Group, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-18 seekingalpha
The following slide deck was published by Sumitomo Mitsui Financial Group, Inc. in conjunction with their 2018 Q1 earnings call.

 
Nikkei rises as financials, tech shares rally

2018-05-17 reuters
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average rose on Thursday after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields while tech shares attracted buyers after the yen weakened.

 
Nikkei rises in line with Wall Street gains; financials rally

2018-05-17 reuters
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average followed U.S. stocks higher on Thursday morning after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields.

 
Sumitomo Mitsui Signals It May Curb Coal-Fired Power Financing - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Total net profit at Japan’s three mega-bank groups likely to grow for first time in four years

2018-05-08 japantimes.co.jp
The total net profit for Japan’s three mega-bank groups are believed to have grown year on year for the first time in four years in the fiscal year that ended in March.

 
Nikkei ekes out small gains on big-cap stocks; Sony stumbles on profit warning

2018-05-01 reuters
TOKYO, May 1 (Reuters) - Japan’s Nikkei eked out modest gains in holiday-thinned trade on Tuesday supported by buying in index-heavy stocks such as Fast Retailing and Fanuc, though Sony tumbled after the company issued a profit warning.

 
Nikkei flat in subdued holiday trade; Sony stumbles on profit warning

2018-05-01 reuters
TOKYO, May 1 (Reuters) - Japanese stocks were choppy in holiday-thinned trade on Tuesday, while Sony tumbled after the company issued a profit warning.

3
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2018 Update

2018-04-27 seekingalpha
Amazon.com, Alibaba Group Holdings, Visa Inc., Apple Inc., and Taiwan Semiconductor Manufacturing are the largest five individual stock positions.

 
UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

2018-04-25 biospace
Takeda Pharmaceutical has come back with an improved bid for Shire for $64 billion, making it the fifth round of talks. Shire is willing to recommend to the board to accept the offer with an extended deal deadline of May 8.

 
Takeda Can't Afford to Kick Its Shire Drug-Takeover Habit - Bloomberg

2018-04-24 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
UPDATE: Takeda Comes Back to the Table, Shire Acquisition Bid Continues to Twist and Turn

2018-04-21 biospace
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan had stated that it “does not intend to make an offer for Shire.”

 
Nikkei flat as tech sector losses offset financials rally

2018-04-20 reuters
TOKYO, April 20 (Reuters) - Japan’s Nikkei share average was flat in choppy trade on Friday morning as worries about slower smartphone demand hit technology shares, while financial stocks rallied helped by higher U.S. yields.

 
Nikkei ends flat as investors worry Trump will pressure Abe on trade

2018-04-17 reuters
TOKYO, April 17 (Reuters) - Japan’s Nikkei ended little changed on Tuesday as investors turned cautious ahead of a meeting between Prime Minister Shinzo Abe and U.S. President Donald Trump which Tokyo fears may link vital security matters with touchy trade issues.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: J7771X109